Table 2 Relationship between CD36 expression and clinicopathology in cervical cancer
Group | CD36 expression | ||||
|---|---|---|---|---|---|
n | Positive | Negative | χ2 | P | |
Age | |||||
≥ 50 | 66 | 51 (77.3%) | 15 (22.7%) | 0.870 | 0.351 |
< 50 | 67 | 47 (70.1%) | 20 (29.9%) | ||
Differentiation | |||||
Good | 48 | 25 (52.1%) | 23 (47.9%) | 18.351 | 0.000* |
Moderate | 42 | 35 (83.3%) | 7 (16.7%) | ||
Poor | 43 | 38 (88.4%) | 5 (11.6%) | ||
Clinical stage | |||||
I | 87 | 66 (75.9%) | 21 (24.1%) | 0.615 | 0.433 |
II–IV | 46 | 32 (69.6%) | 14 (30.4%) | ||
Lymph node metastasis | |||||
Positive | 79 | 64 (81.0%) | 15 (19.0%) | 5.389 | 0.020* |
Negative | 54 | 34 (63.0%) | 20 (37.0%) | ||